Resources

Proteomics Databases



Metabolomics Databases

• • How to Evaluate Hybridoma Sequencing Services: Cost, Timeline, and Deliverables

  Once a team decides to recover VH and VL sequences from a hybridoma, the next questions are often commercial rather than technical. How much should hybridoma sequencing cost? What deliverables justify the expense? Which provider can produce sequence data strong enough for recombinant expression, documentation, or rescue planning?

• • Peptide Sequencing: How LC-MS/MS Determines Amino Acid Sequences from MS/MS Spectra

  Peptide sequence information is often the first concrete answer a project needs. A synthetic peptide may require verification before animal studies. A purified fraction from digestion may contain an unknown peptide that must be identified before the parent protein can be characterized. A biopharmaceutical QC team may need to confirm that a critical peptide fragment matches the expected primary structure.

• • Peptide Sequencing When Interpretation Fails: A Practical Troubleshooting Guide

  A peptide sequencing project can fail quietly. The LC-MS/MS run may complete without error, the precursor mass may look reasonable, yet the MS/MS spectrum shows weak fragmentation, the sequence tag is incomplete, or the database match score is too low to support a confident call. For teams preparing synthetic peptide release, unknown peptide identification, or biologics documentation, this outcome creates immediate delay.

• • Peptide Sequencing vs Database Search: Choosing the Right Peptide Identification Route

  Peptide identification projects rarely fail because teams lack mass spectrometry capability. They fail because the team chooses an identification route that does not match the sample type, reference availability, or required level of evidence. A synthetic peptide may need direct verification against a target design. A digest fraction may contain a peptide with no reliable database entry. A QC workflow may only require confirmation that observed masses match an expected protein sequence.

• • How to Evaluate Peptide Sequencing Services: Cost, Timeline, and Deliverables

  Once a team decides to determine peptide sequence by mass spectrometry, the next questions are often commercial rather than technical. How much should peptide sequencing cost? What deliverables justify the expense? Which provider can produce sequence data strong enough for synthetic release, unknown peptide identification, or documentation review?

• • What Does Histone Kbu Reveal About Chromatin Regulation?

  In the context of advancing research in epigenetic regulation, histone post-translational modifications (PTMs) have expanded beyond traditional acetylation and methylation to include diverse novel acylation forms. Among these, lysine butyrylation (Kbu) of histones, identified as an important modification in recent years, has attracted widespread attention due to its close association with cellular metabolic states. Mediated by butyryl-CoA, Kbu directly integrates metabolic signals into the regulation ......

• • What Are the Common Methods for Histone Malonylation Analysis?

  In the field of epigenetic regulation, histone post-translational modifications (PTMs) are continuously being discovered, expanding our understanding of chromatin biology. Among these, histone propionylation, a novel acylation modification, has garnered increasing attention in recent years. This modification introduces a propionyl group onto lysine residues, altering chromatin structure and protein interactions, thereby influencing gene expression, metabolic reprogramming, and disease progression. Adv......

• • How to Evaluate De Novo Protein Sequencing Services: Cost, Timeline, and Deliverables

  Introduction Once a research team decides that protein-level sequence recovery is necessary, the next challenge is often commercial rather than technical. How much should a de novo protein sequencing project cost? What deliverables justify the expense?

• • Hybridoma Sequencing: How Antibody Variable Region Recovery Works

  Introduction Hybridoma cell lines remain a common source of monoclonal antibodies in discovery, diagnostics, and early development. A hybridoma may produce a useful binder, yet the exact heavy-chain and light-chain variable region sequences may be missing from lab records. Without VH and VL sequence information, teams cannot reliably move to recombinant expression, antibody engineering, sequence documentation, or long-term cell line backup. Hybridoma sequencing is the process of recovering antibody s......

• • De Novo Sequencing: How LC-MS/MS Determines Protein Sequences Without a Database

  Introduction Protein sequence information is often required before a research team can move forward with expression, functional validation, publication, or quality documentation. In many projects, however, no reliable reference sequence exists. The protein may come from an unannotated organism, a proprietary expression system, a legacy purified sample, or a recombinant product that has not yet been fully verified. Standard database-assisted mass spectrometry depends on matching experimental spectra t......